Thanks guys. No slip made on medicare coverage i suppose.
Printable View
Thanks guys. No slip made on medicare coverage i suppose.
It was a public question. It was just a joke. He went on to say that the company would be very profitable.
He did go on about how the business was not like Mitre 10 and the sales cycle is very long.
Also, the lack of patents on key parts of their product was a concern to me.
He did say Japan was the next target country.
He told a great story about how teh patients can order their own tests.
Overall, it was a great presentation, but given they are not Mitre 10, shareholders will need to patient with regard to sales.
The Oryzon deal is a puzzle. PEB sold the exclusive license for "an undisclosed upfront fee along with royalties and sales milestone payments" in May 2011. (there was income of $163000 for license fees in the year to 31/03/12)
http://business.scoop.co.nz/2011/05/...pain-portugal/
Is Oryzon now just sitting on it? Does the uptake hinge on reimbursement by Insurers or the equiv of Medicare in Spain?
I think you will find that the early approaches being rebuffed were based on a not fully commercially available and clinically tested product. This product is now in use commercially after deciding to go alone.
Having gone through all this it is more likely that when sales take off and there is the inevitable takeover offer it will be PEB doing the rebuffing. I agree that the amount about to be restated all over again at the end of the month does not look like much but take that straight (flat line) growth out six months and it looks in the ball park as a rough guide.
IMHO:)
A number of Cxbladder pack sales had gone to share holders at a slight discount in the past. If the sp goes back down 50c to 60c I might buy some and get a discount on a test pack.
Attendees at the AGM could raise this issue. Of course both events are possible, at different times in the past 12 years. I too clearly recall him talking of 'fending off' at takeover proposal
I think it needs to be remembered that this was not a shareholders meeting - there would have been more emphasis put on the product than the financials, of which he could not possibly elaborate on any more than he has told all of us in writing
Balance, did you attend?